Fate Therapeutics, Inc.
A San Diego biotech that grows "off-the-shelf" cell therapies for cancer and autoimmune disease. Using induced pluripotent stem cells — adult cells rewound to an early, flexible state — it programs batches of immune cells (natural killer and T cells) that can be stored and given to many patients, unlike therapies made from each person's own cells. Founded in 2007 by stem-cell scientists, the name comes from its mission to "direct the fate" of cells into specific immune fighters. Its ticker symbol on the stock market is fittingly FATE.
Granted 8.7K · Bought 744.9K · Sold 644.0K
Granted 33.6K
Granted 729.7K · Sold 189.7K
Granted 780.9K · Sold 260.8K
Granted 272.7K · Sold 265.3K
Granted 65.0K · Sold 6.0K
Granted 68.7K · Bought 124.7K · Sold 32.9K
Granted 101.8K · Sold 25.9K
Granted 92.8K · Sold 7.1K
Granted 124.6K · Sold 77.7K
Granted 100.0K
Granted 8.7K · Sold 1.4K
Granted 45.0K · Sold 3.9K
Granted 33.6K
Granted 8.7K
Granted 8.7K · Sold 672
Granted 8.7K · Sold 841
Granted 8.7K · Sold 1.5K
Granted 8.7K · Sold 4.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Green Jeremy +1 co-filerDirector, 10% owner · 16 transactions | — | 38.85Mas of Dec 2024 | 8.7K | 744.9K | 644.0K |
| Rastetter William HDirector · 2 transactions | +5.5% | 642.4K | 33.6K | — | — |
| Valamehr BahramPresident and CEO, Director · 36 transactions | +468.2% | 635.8K | 729.7K | — | 189.7K |
| Tahl CindySee Remarks · 32 transactions | +479.2% | 628.2K | 780.9K | — | 260.8K |
| Wolchko J ScottPresident and CEO, Director · 33 transactions | -5.7% | 371.2Kas of Jan 2024 | 272.7K | — | 265.3K |
| Bressi Jerome CharlesSee Remarks · 2 transactions | — | 335.2Kas of Jan 2025 | 65.0K | — | 6.0K |
| Mendlein JohnDirector · 8 transactions | +95.2% | 311.2Kas of Jan 2023 | 68.7K | 124.7K | 32.9K |
| Chu Yu-WayeChief Medical Officer · 16 transactions | +117.1% | 140.7Kas of Apr 2023 | 101.8K | — | 25.9K |
| Plavsic MarkChief Technical Officer · 4 transactions | +225.5% | 123.7Kas of Jan 2023 | 92.8K | — | 7.1K |
| Dulac Edward J IIIChief Financial Officer · 18 transactions | +86.1% | 101.5Kas of Mar 2024 | 124.6K | — | 77.7K |
| Adawi KamalChief Financial Officer · 2 transactions | — | 100.0K | 100.0K | — | — |
| Coughlin TimothyDirector · 2 transactions | — | 66.3Kas of Jun 2022 | 8.7K | — | 1.4K |
| Powl Brian T.Chief Commercial Officer · 2 transactions | — | 41.1Kas of Jul 2023 | 45.0K | — | 3.9K |
| Epstein Robert SDirector · 2 transactions | +1255.1% | 36.3K | 33.6K | — | — |
| Lee Michael StewartDirector · 1 transaction | +322.6% | 11.3Kas of Jun 2022 | 8.7K | — | — |
| Hershberg RobertDirector · 2 transactions | +297.6% | 10.7Kas of Jun 2022 | 8.7K | — | 672 |
| Agarwal ShefaliDirector · 3 transactions | +291.3% | 10.5Kas of Jun 2022 | 8.7K | — | 841 |
| Jooss KarinDirector · 2 transactions | +267.3% | 9.8Kas of Jun 2022 | 8.7K | — | 1.5K |
| Xu YuanDirector · 4 transactions | +82.7% | 8.7Kas of Aug 2024 | 8.7K | — | 4.7K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -652.7K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.